


## Dot1L-IN-1

<b>Cat. No.:</b>	HY-101520
<b>CAS No.:</b>	2088518-50-5
<b>Molecular Formula:</b>	C <sub>32</sub> H <sub>36</sub> ClN <sub>9</sub> O <sub>2</sub> S
<b>Molecular Weight:</b>	646.21
<b>Target:</b>	Histone Methyltransferase
<b>Pathway:</b>	Epigenetics
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Dot1L-IN-1 is a highly potent and selective Dot1L inhibitor with a K <sub>i</sub> of 2 pM and an IC <sub>50</sub> of <0.1 nM. Dot1L-IN-1 potently suppresses H3K79 dimethylation (IC <sub>50</sub> =3 nM), as well as the activity of the HoxA9 promoter (IC <sub>50</sub> =17 nM) in HeLa and Molm-13 cells, respectively <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	DOT1L
<b>In Vitro</b>	Dot1L-IN-1 (analogue 7) effectively inhibits proliferation of the human MLL-rearranged leukemia cell line MV4-11 carrying the oncogenic MLL-AF4 fusion (IC <sub>50</sub> =5 nM) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Möbitz H, et al. Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach. ACS Med Chem Lett. 2017 Feb 14;8(3):338-343.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA